Anavex to Present Initial Clinical Data from the Phase 2a Clinical Trial of ANAVEX 2-73 at the Alzheimer’s Association International Conference (AAIC)
Anavex Encouraged by Data Showing Sigma-1 Receptor Reduces Tau Dysfunction, a Hallmark of Alzheimer’s Disease
Anavex Releases Promising Full Preclinical Epilepsy Data at Antiepileptic Drug Trials XIII Conference
Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference
Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain Injuries
Anavex Presents Positive Results for Both ANAVEX 2-73 and ANAVEX 3-71 in Alzheimer’s Models at 2015 AD/PD™ Conference
